AVITA Medical, Inc. RCEL

Company Overview

AVITA Medical, Inc. is a regenerative medicine and medical technology company focused on developing and commercializing autologous cell harvesting and skin restoration technologies for patients with thermal burn injuries, full-thickness skin defects, chronic wounds, and aesthetic skin applications. The company operates within the broader healthcare, biotechnology, and advanced wound care industries, with its core commercial platform centered on the RECELL System, a point-of-care device designed to prepare Spray-On Skin Cells using a patient’s own skin tissue.

The company’s primary revenue driver is sales of the RECELL platform and related procedural consumables to hospitals and burn centers, primarily in the United States. AVITA has positioned itself within regenerative medicine through a differentiated approach that seeks to reduce donor skin requirements and improve healing outcomes compared with traditional grafting procedures. Originally founded in Australia, the company evolved from research into skin regeneration technologies and later expanded its commercial focus into the U.S. market after obtaining approvals from the U.S. Food and Drug Administration. Public filings and investor materials identify advanced wound care and soft tissue repair as key long-term growth categories for the company.